Literature DB >> 24795043

Adapter protein Shc regulates Janus kinase 3 phosphorylation.

Jayshree Mishra1, Narendra Kumar2.   

Abstract

Although constitutive activation of Janus kinase 3 (Jak3) leads to different cancers, the mechanism of trans-molecular regulation of Jak3 activation is not known. Previously we reported that Jak3 interactions with adapter protein p52ShcA (Shc) facilitate mucosal homeostasis. In this study, we characterize the structural determinants that regulate the interactions between Jak3 and Shc and demonstrate the trans-molecular mechanism of regulation of Jak3 activation by Shc. We show that Jak3 autophosphorylation was the rate-limiting step during Jak3 trans-phosphorylation of Shc where Jak3 directly phosphorylated two tyrosine residues in Src homology 2 (SH2) domain and one tyrosine residue each in calponin homology 1 (CH1) domain and phosphotyrosine interaction domain (PID) of Shc. Direct interactions between mutants of Jak3 and Shc showed that although FERM domain of Jak3 was sufficient for binding to Shc, CH1 and PID domains of Shc were responsible for binding to Jak3. Functionally Jak3 was autophosphorylated under IL-2 stimulation in epithelial cells. However, Shc recruited tyrosine phosphatases SHP2 and PTP1B to Jak3 and thereby dephosphorylated Jak3. Thus we not only characterize Jak3 interaction with Shc, but also demonstrate the molecular mechanism of intracellular regulation of Jak3 activation where Jak3 interactions with Shc acted as regulators of Jak3 dephosphorylation through direct interactions of Shc with both Jak3 and tyrosine phosphatases.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Apoptosis; Janus Kinase (JAK); Nonreceptor Tyrosine Kinase (nRTK); Phosphatase; Protein Phosphatase; Wound Healing

Mesh:

Substances:

Year:  2014        PMID: 24795043      PMCID: PMC4047368          DOI: 10.1074/jbc.C113.527523

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  The ShcA phosphotyrosine docking protein sensitizes cardiovascular signaling in the mouse embryo.

Authors:  K M Lai; T Pawson
Journal:  Genes Dev       Date:  2000-05-01       Impact factor: 11.361

2.  Identification of a functional switch for actin severing by cytoskeletal proteins.

Authors:  Narendra Kumar; Seema Khurana
Journal:  J Biol Chem       Date:  2004-04-14       Impact factor: 5.157

Review 3.  Not all Shc's roads lead to Ras.

Authors:  L Bonfini; E Migliaccio; G Pelicci; L Lanfrancone; P G Pelicci
Journal:  Trends Biochem Sci       Date:  1996-07       Impact factor: 13.807

4.  Protein phosphatase 2A forms a molecular complex with Shc and regulates Shc tyrosine phosphorylation and downstream mitogenic signaling.

Authors:  Satoshi Ugi; Takeshi Imamura; William Ricketts; Jerrold M Olefsky
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

5.  JAK3: expression and mapping to chromosome 19p12-13.1.

Authors:  M G Safford; M Levenstein; E Tsifrina; S Amin; A L Hawkins; C A Griffin; C I Civin; D Small
Journal:  Exp Hematol       Date:  1997-05       Impact factor: 3.084

6.  The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor.

Authors:  L J Huang; S N Constantinescu; H F Lodish
Journal:  Mol Cell       Date:  2001-12       Impact factor: 17.970

7.  Role of Janus kinase 3 in mucosal differentiation and predisposition to colitis.

Authors:  Jayshree Mishra; Raj K Verma; Gianfranco Alpini; Fanyin Meng; Narendra Kumar
Journal:  J Biol Chem       Date:  2013-09-17       Impact factor: 5.157

8.  Functional dissection and molecular characterization of calcium-sensitive actin-capping and actin-depolymerizing sites in villin.

Authors:  Narendra Kumar; Alok Tomar; Abby L Parrill; Seema Khurana
Journal:  J Biol Chem       Date:  2004-07-21       Impact factor: 5.157

9.  Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID).

Authors:  P Macchi; A Villa; S Giliani; M G Sacco; A Frattini; F Porta; A G Ugazio; J A Johnston; F Candotti; J J O'Shea
Journal:  Nature       Date:  1995-09-07       Impact factor: 49.962

10.  c-Src and phosphatidylinositol 3-kinase are involved in NGF-dependent tyrosine phosphorylation of Shc in PC12 cells.

Authors:  K Sato; T Otsuki; M Kimoto; M Kakumoto; A A Tokmakov; Y Watanabe; Y Fukami
Journal:  Biochem Biophys Res Commun       Date:  1998-09-18       Impact factor: 3.575

View more
  7 in total

1.  Role of Janus Kinase 3 in Predisposition to Obesity-associated Metabolic Syndrome.

Authors:  Jayshree Mishra; Raj K Verma; Gianfranco Alpini; Fanyin Meng; Narendra Kumar
Journal:  J Biol Chem       Date:  2015-10-08       Impact factor: 5.157

2.  Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.

Authors:  Jayshree Mishra; Randall Simonsen; Narendra Kumar
Journal:  J Biol Chem       Date:  2019-10-25       Impact factor: 5.157

3.  A case of aberrant CD8 T cell-restricted IL-7 signaling with a Janus kinase 3 defect-associated atypical severe combined immunodeficiency.

Authors:  Aaruni Khanolkar; Jeffrey D Wilks; Guorong Liu; Bridget M Simpson; Edward A Caparelli; Dawn A Kirschmann; Jenna Bergerson; Ramsay L Fuleihan
Journal:  Immunol Res       Date:  2020-02       Impact factor: 2.829

4.  Janus kinase 3 regulates adherens junctions and epithelial mesenchymal transition through β-catenin.

Authors:  Jayshree Mishra; Jugal Kishore Das; Narendra Kumar
Journal:  J Biol Chem       Date:  2017-08-17       Impact factor: 5.157

Review 5.  Mucosal Epithelial Jak Kinases in Health and Diseases.

Authors:  Narendra Kumar; Longxiang Kuang; Ryan Villa; Priyam Kumar; Jayshree Mishra
Journal:  Mediators Inflamm       Date:  2021-03-16       Impact factor: 4.711

6.  Mechanistic Role of Jak3 in Obesity-Associated Cognitive Impairments.

Authors:  Premranjan Kumar; Jayshree Mishra; Narendra Kumar
Journal:  Nutrients       Date:  2022-09-09       Impact factor: 6.706

Review 7.  Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors.

Authors:  Ryuhjin Ahn; Josie Ursini-Siegel
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.